Mittie Doyle

Mittie Doyle currently serves as an Independent Board Member at Santa Ana Bio, Inc. and as Chief Medical Officer at Aro Biotherapeutics. Previous roles include Independent Board Member at DICE Therapeutics until its acquisition by Eli Lilly & Co., Vice President and Group Head of Immunology and Inflammation at CSL Behring, and Global Development Lead at Shire. Mittie Doyle has extensive experience in clinical research and development, having held senior positions at Flexion Therapeutics, Alexion Pharmaceuticals, and Centocor. An academic background includes a Doctor of Medicine (MD) from Harvard Medical School and a BA in Romance Languages from Princeton University.